1382998-73-3

Upstream product

• 149806-06-4 6-bromonicotinaldehyde 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 1383001-88-4 2-[4-(benzyloxy)phenyl]-5-[4-(trifluoro-methyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl]pyridine 
• 1383001-87-3 2-bromo-5-[5-(trifluoromethyl)-1H-imidazole-2-yl]pyridine 
• 1382998-88-0 2-bromo-5-[4-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-yl]pyridine 

Downstream Products

• 1382998-74-4 methyl 2,2-dimethyl-3-(4-{5-[4-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl]pyridin-2-yl}phenoxy)propanoate 
• 1382999-42-9 methyl 2-ethyl-2-[[4-[5-[4-(trifluoro-methyl)-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]-2-pyridyl]phenoxy]methyl]-butanoate 

Relevant academic research and scientific papers

AROMATIC HETEROCYCLIC COMPOUND

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

CONTINUOUS ARYCYCLIC COMPOUND

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension,